{"disease":{"id":"factor-viii","name":"factor viii"},"drugs":{"marketed":[{"drug_id":"emicizumab","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hemlibra","generic_name":"EMICIZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"Coagulation factor IX","drug_class":"","quality_score":63,"revenue":"4800","mechanism":"Hemlibra works by binding to and activating factor IXa, a protein involved in blood clotting, to bypass the need for factor VIII."},{"drug_id":"fitusiran","indication_name":"Factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qfitlia","generic_name":"FITUSIRAN","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Antithrombin-directed RNA Interaction [EPC]","quality_score":10,"revenue":"400","mechanism":"Qfitlia works by using small RNA molecules to block the production of antithrombin, a protein that can interfere with blood clotting."},{"drug_id":"minirin","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minirin","company_name":"Hormozgan University of Medical Sciences","drug_phase":"marketed","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"efmoroctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocta","generic_name":"EFMOROCTOCOG ALFA","company_name":"Swedish Orphan Biovitrum AB","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"valoctocogene-roxaparvovec","indication_name":"Severe hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roctavian","generic_name":"VALOCTOCOGENE ROXAPARVOVEC","company_name":"BioMarin International Limited","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":43,"revenue":null,"mechanism":"Roctavian introduces a functional copy of the F8 gene into cells to produce factor VIII protein."},{"drug_id":"moroctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Refacto Af","generic_name":"MOROCTOCOG ALFA","company_name":"Pfizer Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"susoctocog-alfa","indication_name":"Acquired factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Obizur","generic_name":"SUSOCTOCOG ALFA","company_name":"Baxalta Innovations GmbH","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl3990039","indication_name":"hemophilia A (congenital factor VIII deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"MARSTACIMAB","company_name":"Pfizer Inc","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":"Hympavzi works by binding to Factor Xa, a protein involved in blood clotting."},{"drug_id":"chembl-chembl3990039","indication_name":"hemophilia A (congenital factor VIII deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"MARSTACIMAB","company_name":"Pfizer Inc","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":"Hympavzi works by binding to Factor Xa, a protein involved in blood clotting."},{"drug_id":"turoctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novoeight","generic_name":"TUROCTOCOG ALFA","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"concizumab","indication_name":"hemophilia A (congenital factor VIII deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"octocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advate","generic_name":"OCTOCOG ALFA","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"simoctocog-alfa","indication_name":"Factor VIII deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuwiq","generic_name":"SIMOCTOCOG ALFA","company_name":"Octapharma AB","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"simoctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuwiq","generic_name":"SIMOCTOCOG ALFA","company_name":"Octapharma AB","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"desmopressin","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ddavp","generic_name":"DESMOPRESSIN","company_name":"Ferring Pharms Inc","drug_phase":"marketed","molecular_target":"Vasopressin V1b receptor","drug_class":"Factor VIII Activator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"eloctate","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eloctate","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"argipressin","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Argipressin","company_name":"Kristina Svennerholm","drug_phase":"marketed","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"esperoct","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Esperoct","company_name":"Novo Nordisk A/S","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nuwiq","indication_name":"Factor VIII deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nuwiq","company_name":"Emory University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lonoctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afstyla","generic_name":"LONOCTOCOG ALFA","company_name":"CSL Behring GmbH","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"nuwiq","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nuwiq","company_name":"Emory University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"eptacog-alfa-activated","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eptacog Alfa","generic_name":"EPTACOG ALFA (ACTIVATED)","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":24,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05628558","title":"Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Groupe Maladies hémorragiques de Bretagne","has_results":false},{"nct_id":"NCT06020456","title":"Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A","phase":"","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Groupe Maladies hémorragiques de Bretagne","has_results":false},{"nct_id":"NCT04161495","title":"A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":true},{"nct_id":"NCT04165135","title":"An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04158648","title":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02093741","title":"ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT03006965","title":"Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Spanish Society of Thrombosis and Haemostasis","has_results":false},{"nct_id":"NCT06941870","title":"Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03876301","title":"Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03734588","title":"Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":true}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}